Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis GCP / Pharmacovigilance Inspections by Year
Novartis GCP / Pharmacovigilance Inspections: 23 in FY2025, up 9.5% from a year earlier.
Latest, FY2025
23
Period ended Dec 31, 2025
Change on a year earlier
+9.5%
21 in FY2024
History
2 years
Since FY2024
Sources
1
Novartis Official IR / Sustainability Report — novartis-esg-data-summary-2025.pdf
Where the FY2025 figure comes from
“| Inspections related to clinical trial management and/or pharmacovigilance | 23 | 21”
Source: Novartis Official IR / Sustainability Report — novartis-esg-data-summary-2025.pdf ↗
Reported in ESG Data Summary 2025.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | GCP / Pharmacovigilance Inspections | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 23 | +9.5% | Novartis Official IR / Sustainability Report — novartis-esg-data-summary-2025.pdf ↗ |
| FY2024 | Dec 31, 2024 | 21 | – | Novartis Official IR / Sustainability Report — novartis-esg-data-summary-2025.pdf ↗ |
Cite this data
StockData. (2026). Novartis GCP / Pharmacovigilance Inspections, annual FY2024–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/qual-gcp-pv-inspections
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.